These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9392740)

  • 41. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
    Spinowitz BS; Pratt RD;
    Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
    Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
    Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
    Bieber E
    J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of epoetin dose on hematocrit.
    Cotter D; Zhang Y; Thamer M; Kaufman J; Hernán MA
    Kidney Int; 2008 Feb; 73(3):347-53. PubMed ID: 18004296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY; Chu TS; Huang JW; Wu MS; Wu KD
    J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Case study of the anemic patient: epoetin alfa--focus on improving ventricular function.
    Weil C
    ANNA J; 1995 Jun; 22(3):338-41. PubMed ID: 7786083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
    Messana T
    Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case study of the anemic patient: epoetin alfa--focus on CQI and patient management.
    Kammerer JK
    ANNA J; 1994 Aug; 21(5):282-5. PubMed ID: 8080342
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
    Kimel M; Leidy NK; Mannix S; Dixon J
    Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time to consider the role of epoetin.
    Zhang Y; Thamer M
    Kidney Int; 2006 May; 69(10):1917; author reply 1917-8. PubMed ID: 16688199
    [No Abstract]   [Full Text] [Related]  

  • 56. Erythropoietic agents in peritoneal dialysis.
    Muirhead N
    Perit Dial Int; 2005; 25(6):547-50. PubMed ID: 16411519
    [No Abstract]   [Full Text] [Related]  

  • 57. Case study of the anemic patient: epoetin alfa--focus on protocols.
    Kammerer JK
    ANNA J; 1994 Dec; 21(7):440-3. PubMed ID: 7872824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.
    Saag MS; Bowers P; Leitz GJ; Levine AM;
    AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1037-45. PubMed ID: 15587490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.